HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

Benzinga · 1d ago
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.